Health insurance coverage in the USA is declining, driven by the expiration of enhanced Affordable Care Act (ACA) subsidies and post-pandemic Medicaid unwinding. Millions are dropping out of the market due to unaffordable premiums, while those who retain plans face narrower networks, stricter coverage denials, and higher out-of-pocket costs. The decline in US health insurance […]
Archive for June, 2026
๐๐๐ง ๐ญ๐ก๐ ๐๐ ๐๐๐๐จ๐ฆ๐ ๐ ๐๐ก๐ข๐ซ๐ ๐๐จ๐ซ๐ฅ๐ ๐๐จ๐ฎ๐ง๐ญ๐ซ๐ฒ? ๐๐ก๐ ๐๐ซ๐ข๐ฉ, ๐๐ซ๐ข๐ฉ, ๐๐ซ๐ข๐ฉ ๐จ๐ ๐๐๐๐ฅ๐ข๐ง๐ข๐ง๐ ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐จ๐ฏ๐๐ซ๐๐ ๐.
Posted by Michael A. S. Guth on June 11th, 2026
Posted in Pharma and Medical Device, Regulatory Medical Writing 
Comments Off on ๐๐๐ง ๐ญ๐ก๐ ๐๐ ๐๐๐๐จ๐ฆ๐ ๐ ๐๐ก๐ข๐ซ๐ ๐๐จ๐ซ๐ฅ๐ ๐๐จ๐ฎ๐ง๐ญ๐ซ๐ฒ? ๐๐ก๐ ๐๐ซ๐ข๐ฉ, ๐๐ซ๐ข๐ฉ, ๐๐ซ๐ข๐ฉ ๐จ๐ ๐๐๐๐ฅ๐ข๐ง๐ข๐ง๐ ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐จ๐ฏ๐๐ซ๐๐ ๐.๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐ฆ๐จ๐ฌ๐ญ ๐ก๐๐ซ๐ฆ๐๐ฎ๐ฅ ๐๐จ๐จ๐ ๐ข๐ง๐ ๐ซ๐๐๐ข๐๐ง๐ญ๐ฌ ๐ญ๐ก๐๐ญ ๐๐จ๐ง๐ญ๐ซ๐ข๐๐ฎ๐ญ๐ ๐ญ๐จ ๐๐๐ฆ๐๐ง๐ญ๐ข๐ ๐ซ๐ข๐ฌ๐ค?
Posted by Michael A. S. Guth on June 10th, 2026
The most harmful industrial ingredients contributing to dementia risk are processed meat preservatives (nitrites/nitrates), added sugars (high-fructose corn syrup), and chemical additives like emulsifiers. Rather than focusing on a single nutrient, public health studiesโincluding recent 2026 data from the Harvard T.H. Chan School of Public Healthโpoint to specific chemical formulations and industrial ingredients that directly […]
Posted in Neuroplasticity, Regulatory Medical Writing Comments Off on ๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐ฆ๐จ๐ฌ๐ญ ๐ก๐๐ซ๐ฆ๐๐ฎ๐ฅ ๐๐จ๐จ๐ ๐ข๐ง๐ ๐ซ๐๐๐ข๐๐ง๐ญ๐ฌ ๐ญ๐ก๐๐ญ ๐๐จ๐ง๐ญ๐ซ๐ข๐๐ฎ๐ญ๐ ๐ญ๐จ ๐๐๐ฆ๐๐ง๐ญ๐ข๐ ๐ซ๐ข๐ฌ๐ค?Demystifying Long-Horizon Survival Forecasting in Oncology HTAโPerspective Manuscript
Posted by Michael A. S. Guth on June 9th, 2026
Dear Drs. xxxxxxxxxxxx and xxxxxxxxxxxxxxx, I write to inquire whether the Journal of Clinical Epidemiology would consider a Perspective manuscript entitled xxxxxxxxxxxxxxxxxxxxxxxx. The manuscript (~5,100 words, 37 references) addresses a problem that experienced clinical epidemiologists and HTA reviewers recognize but that the published literature has been reluctant to name directly: when Phase 3 trials produce […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on Demystifying Long-Horizon Survival Forecasting in Oncology HTAโPerspective ManuscriptAdeno-associated virus serotype 9 (AAV9): tool of gene therapy that crosses the BBB
Posted by Michael A. S. Guth on June 4th, 2026
Adeno-associated virus serotype 9 (AAV9) is highly valued in gene therapy because it can cross the blood-brain barrier. It is primarily used to treat monogenic neurological and neuromuscular disorders, most notably Spinal Muscular Atrophy (SMA). AAV9 vectors deliver functional genetic material to replace or suppress faulty genes. Approved treatments and advanced clinical trials using AAV9 […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on Adeno-associated virus serotype 9 (AAV9): tool of gene therapy that crosses the BBBHEOR Survival Statistics and Data Shading
Posted by Michael A. S. Guth on June 4th, 2026
๐๐ก๐๐ง ๐ ๐๐ซ๐ฎ๐ ๐ฌ๐ก๐จ๐ฐ๐ฌ ๐ ๐ก๐๐ณ๐๐ซ๐ ๐ซ๐๐ญ๐ข๐จ ๐จ๐ ๐.๐๐ โ ๐ฐ๐ก๐ข๐๐ก ๐ฌ๐จ๐ฎ๐ง๐๐ฌ ๐ข๐ฆ๐ฉ๐ซ๐๐ฌ๐ฌ๐ข๐ฏ๐ โ ๐๐ง๐ ๐ญ๐ก๐ ๐ญ๐ซ๐ข๐๐ฅ ๐ฆ๐๐๐ข๐๐ง ๐ฌ๐ฎ๐ซ๐ฏ๐ข๐ฏ๐๐ฅ ๐ฐ๐๐ฌ ๐๐ ๐ฆ๐จ๐ง๐ญ๐ก๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐๐จ๐ง๐ญ๐ซ๐จ๐ฅ ๐๐ซ๐ฆ, ๐ญ๐ก๐ ๐ฆ๐๐ญ๐ก ๐ฐ๐จ๐ซ๐ค๐ฌ ๐จ๐ฎ๐ญ ๐ญ๐จ ๐ซ๐จ๐ฎ๐ ๐ก๐ฅ๐ฒ ๐ ๐๐๐๐ข๐ญ๐ข๐จ๐ง๐๐ฅ ๐ฆ๐จ๐ง๐ญ๐ก๐ฌ ๐๐ญ ๐ญ๐ก๐ ๐ฆ๐๐๐ข๐๐ง. ๐๐จ๐ญ ๐ฒ๐๐๐ซ๐ฌ. ๐๐จ๐ง๐ญ๐ก๐ฌ. ๐๐จ๐ฆ๐๐ญ๐ข๐ฆ๐๐ฌ ๐ฐ๐๐๐ค๐ฌ. The drug costs $28,000/month. If a cancer drug showed “statistically significant survival […]